Overview
- The U.S. Food and Drug Administration has authorized the first generic version of baloxavir marboxil, the active ingredient in Xofluza, for use in the United States.
- The generic keeps the single‑dose format and is approved for people age 5 and older to treat uncomplicated influenza within 48 hours of symptom onset and for post‑exposure prevention.
- Clinical studies show baloxavir can shorten illness, reduce household transmission, and may lower hospital admissions in some high‑risk patients compared with other antivirals.
- Generic availability is likely to improve affordability and patient adherence but actual price cuts and insurance coverage will depend on manufacturer rollout and payer decisions.
- Public health experts stress that antivirals are a time‑sensitive treatment, not a substitute for the annual flu vaccine, so people should get vaccinated and seek care quickly if symptoms start.